Kairos Discovery
Biotech company (Lyon, France) developing next-generation targeted cancer therapies focused on kinases. The organization applies medicinal chemistry, structural biology, and PK/PD-guided optimization to advance small-molecule modalities (including a bivalent CK2α inhibitor and CDK-targeted protein degraders) through preclinical development toward clinical entry. Activities include lead optimization, in vitro and in vivo pharmacology, CMC and IND-enabling preparations, and biomarker-informed indication strategies.
Industries
Nr. of Employees
small (1-50)
Kairos Discovery
36 Rue Jeanne d'Arc, 69003 Lyon, France
Products
Bivalent CK2α small-molecule inhibitor (lead candidate)
A bivalent small-molecule designed to engage both the ATP-binding pocket and a neighboring allosteric site on the CK2α subunit to increase selectivity, prolong engagement, and modulate catalytic and non-catalytic functions.
CDK-targeted protein degrader candidates
Drug discovery program focused on degraders of cyclin-dependent kinases as an alternative modality to direct enzymatic inhibition.
Bivalent CK2α small-molecule inhibitor (lead candidate)
A bivalent small-molecule designed to engage both the ATP-binding pocket and a neighboring allosteric site on the CK2α subunit to increase selectivity, prolong engagement, and modulate catalytic and non-catalytic functions.
CDK-targeted protein degrader candidates
Drug discovery program focused on degraders of cyclin-dependent kinases as an alternative modality to direct enzymatic inhibition.
Services
Joint research and translational collaborations to advance oncology programs through discovery and preclinical validation.
Joint research and translational collaborations to advance oncology programs through discovery and preclinical validation.
Expertise Areas
- Targeted oncology drug discovery
- Medicinal chemistry
- Structure-guided drug design
- Preclinical pharmacology and translational models
Key Technologies
- Medicinal chemistry
- Structural biology
- PK/PD optimization
- Bivalent small-molecule inhibitors
News & Updates
Discusses the role of medicinal chemistry in designing selective cancer therapeutics and translating research into clinical candidates.
Overview of challenges with traditional kinase inhibitors and strategies (selectivity, combination therapy) to improve durability and reduce adverse effects.
Explores therapeutic approaches that target kinase functions beyond catalytic inhibition to affect signaling pathways more effectively.
Describes the mechanism and potential advantages of bivalent inhibitors that bind two sites to improve selectivity and efficacy.
Summarizes CK2 biology, its role in tumor development, and rationale for prioritizing CK2 in drug discovery.
First peer-reviewed data from the lead program published in the journal iScience.
Discusses the role of medicinal chemistry in designing selective cancer therapeutics and translating research into clinical candidates.
Overview of challenges with traditional kinase inhibitors and strategies (selectivity, combination therapy) to improve durability and reduce adverse effects.
Explores therapeutic approaches that target kinase functions beyond catalytic inhibition to affect signaling pathways more effectively.
Describes the mechanism and potential advantages of bivalent inhibitors that bind two sites to improve selectivity and efficacy.
Summarizes CK2 biology, its role in tumor development, and rationale for prioritizing CK2 in drug discovery.
First peer-reviewed data from the lead program published in the journal iScience.